University of Thessaly (UTH)
Σίγμα υποδοχείς: μελέτη του ρόλου τους στην καρκινογένεση και στην ανάπτυξη νέων έξυπνων στοχευμένων αντικαρκινικών θεραπειών
Abstract
dc:descriptionSigma receptors have attracted research interest as they have been proposed as therapeutic targets for the treatment of various diseases and pathological conditions, including some types of cancer. They consist of two subtypes, sigma-1 (σ1) and sigma-2 (σ2), however, the identification of σ2 is under investigation. Until recently it was related to the PGRMC1 receptor while a later theory identifies it with the TMEM97 receptor. Also, some ligands exhibit significant antiproliferative and cytotoxic activity in various types of cancer. However, the precise mechanism of action of both sigma receptors and their ligands remains unclear and remains to be elucidated.In the present doctoral thesis, the levels of σ receptor expression (σ1, σ2/PGRMC1, and σ2/TMEM97) in human established and primary cancer cell lines were investigated. For the first time in the literature, the simultaneous determination of the expression levels of the σ1 receptor and the σ2/TMEM97 and σ2/PGRMC1 receptors was performed simultaneously. Subsequently, the in vitro anticancer activity of some widely used σ1 and σ2 ligands against various types of cancer was studied. Their activity was compared under the same experimental conditions and their possible mechanism of action was investigated. Finally, the ligand that exhibited the best in vitro antiproliferative activity (Siramesine) was more extensively studied in primary patient-derived xenografts (PDX). The expression levels of the σ receptors were determined by Western blot. The antiproliferative activity of the ligands against 24 cancer cell lines was studied using the sulforhodamine B (SRB) assay. The COMPARE algorithm was used for the estimation of the mechanism of action of the ligands. The efficacy of Siramesine (monotherapy or in combination with Gemcitabine) was tested on cancer animal models derived from patients with pancreatic cancer (PDX) that were developed in our laboratory. From the present study, there is no direct correlation between the σ1 and σ2 receptors with cancer type and tumor aggression. In addition, it seems that the substances tested here, even though they have significant in vitro anticancer activity, exert this effect through mechanisms that do not involve the receptors. Among the tested σ ligands, Siramesine appeared to be the most promising. Studies of Siramesine, in tumor xenografts derived from patients (PDX) that were held for the first time under the present thesis, confirmed its good anticancer activity. Also, our experimental data show that Siramesine can be combined with other chemotherapeutics to improve the therapeutic effect. The major disadvantage of the substance appears to be some of its increased toxicity but it can be overcome, as the corresponding study using controlled release drug nanoparticles such as liposomes, has shown.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Sereti, Evangelia
- Σερέτη, Ευαγγελία
Subjects
dc:subject × 8Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46489